Kristin Hamilton - Lexaria Bioscience Director Operations

LEXX Stock  USD 2.13  0.02  0.93%   

Director

Kristin Hamilton is Director Operations of Lexaria Bioscience Corp
Address 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7
Phone250 765 6424
Webhttps://lexariabioscience.com

Lexaria Bioscience Management Efficiency

The company has return on total asset (ROA) of (0.3821) % which means that it has lost $0.3821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7066) %, meaning that it created substantial loss on money invested by shareholders. Lexaria Bioscience's management efficiency ratios could be used to measure how well Lexaria Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.14 in 2024, whereas Return On Tangible Assets are likely to drop (0.55) in 2024. At this time, Lexaria Bioscience's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.3 M in 2024, whereas Total Current Assets are likely to drop slightly above 2.2 M in 2024.
Lexaria Bioscience Corp currently holds 163.97 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lexaria Bioscience Corp has a current ratio of 39.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lexaria Bioscience's use of debt, we should always consider it together with its cash and equity.
Lexaria Bioscience Corp. operates as a biotechnology company. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States. Lexaria Bioscience Corp (LEXX) is traded on NASDAQ Exchange in USA. It is located in 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 and employs 5 people. Lexaria Bioscience is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Lexaria Bioscience Corp Leadership Team

Elected by the shareholders, the Lexaria Bioscience's board of directors comprises two types of representatives: Lexaria Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lexaria. The board's role is to monitor Lexaria Bioscience's management team and ensure that shareholders' interests are well served. Lexaria Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lexaria Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Christopher Bunka, Chairman CEO
Vanessa Carle, Head Legal
Philip Ainslie, Advisor Consultant
Nelson CPA, Chief Officer
CPA CMA, Chief Officer
Richard Christopher, Chief Officer
John MSc, President Director
Michael CPA, Chief Officer
Michael Shankman, Chief Officer
Kristin Hamilton, Director Operations
Mike Shankman, Chief Officer

Lexaria Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lexaria Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.